Compare XELB & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XELB | CANF |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 6.7M |
| IPO Year | 2011 | 2011 |
| Metric | XELB | CANF |
|---|---|---|
| Price | $0.36 | $1.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.00 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.4M | 24.4K |
| Earning Date | 11-18-2026 | 09-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.13 | N/A |
| Revenue Next Year | $99.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.17 |
| 52 Week High | $2.47 | $10.40 |
| Indicator | XELB | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 26.27 | 28.80 |
| Support Level | $0.27 | $1.75 |
| Resistance Level | $1.16 | $2.27 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.71 | 11.79 |
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.